Kyowa Pharmaceutical Industry Co., Ltd. (Head office: Yodogawa-ku, Osaka City, President and Representative Director: Ray Tsunoda, hereinafter called 'Kyowa') and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, 'Astellas') today announced that the companies have entered into an agreement providing Kyowa the exclusive right to distribute and promote extended-release tablets of quetiapine fumarate in Japan. Astellas submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine fumarate for the indication of improvement of depressive symptoms associated with bipolar disorder.

When Astellas obtains an approval for the new drug application of extended-release tablets of quetiapine fumarate, based on the agreement, Kyowa will exclusively distribute and promote the products in Japan.

###

Astellas Pharma Inc. published this content on 27 February 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 27 February 2017 06:11:02 UTC.

Original documenthttps://www.astellas.com/en/corporate/news/detail/kyowa-and-astellas-enter-into-.html

Public permalinkhttp://www.publicnow.com/view/CAF8FDE77B06FCD9D3C722FA50285E07AB49D059